2021
Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: a European Society of Thoracic Surgeons Thymic Working Group Study
Guerrera F, Falcoz PE, Moser B, van Raemdonck D, Bille’ A, Toker A, Spaggiari L, Ampollini L, Filippini C, Thomas PA, Verdonck B, Mendogni P, Aigner C, Voltolini L, Novoa N, Patella M, Mantovani S, Bravio IG, Zisis C, Guirao A, Londero F, Congregado M, Rocco G, Du Pont B, Martucci N, Esch M, Brunelli A, Detterbeck FC, Venuta F, Weder W, Ruffini E, Centers T, Klepetko W, Olland A, Du Pont B, Nonaka D, Ozkan B, Iacono G, Braggio C, Filosso P, Brioude G, van Schil P, Nosotti M, Valdivia D, Bongiolatti S, Inci I, Dimitra R, Sànchez D, Grossi W, Moreno-Merino S, Teschner M. Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: a European Society of Thoracic Surgeons Thymic Working Group Study. European Journal Of Cardio-Thoracic Surgery 2021, 60: 881-887. PMID: 34023891, PMCID: PMC10060729, DOI: 10.1093/ejcts/ezab224.Peer-Reviewed Original ResearchConceptsEarly-stage thymomaMyasthenia gravisTT groupST groupPropensity score-adjusted comparisonsNon-MG patientsPathological stage IPostoperative morbidity rateEuropean SocietyRate of complicationsCompleteness of resectionOverall survival rateLong-term outcomesProcedure of choiceMost relevant articlesOncological standpointCurative intentPostoperative complicationsPostoperative lengthTotal thymectomyOverall recurrenceThymic tumorsMorbidity rateSurgical approachThymus gland
2020
Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis
Jiang R, Hoehn KB, Lee CS, Pham MC, Homer RJ, Detterbeck FC, Aban I, Jacobson L, Vincent A, Nowak RJ, Kaminski HJ, Kleinstein SH, O'Connor KC. Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 30649-30660. PMID: 33199596, PMCID: PMC7720237, DOI: 10.1073/pnas.2007206117.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAutoantibodiesB-LymphocytesBiomarkersClonal EvolutionClonal Selection, Antigen-MediatedDisease SusceptibilityFemaleHumansLymphocyte CountMaleMiddle AgedModels, BiologicalMyasthenia GravisRadioimmunoassayReceptors, CholinergicThymectomyThymus GlandV(D)J RecombinationYoung AdultConceptsB cell clonesMyasthenia gravisB cell repertoireB cellsCell clonesPlasma cellsCell repertoireAdditional immunosuppressive treatmentDiminished clinical responseThymic lymphofollicular hyperplasiaComplete stable remissionMajority of patientsAntigen-experienced B cellsRandomized clinical trialsClinical symptom measuresAChR autoantibodiesImmunosuppressive treatmentSteroid doseAutoantibody titersMG thymusClinical responseStable remissionClinical scoresAutoimmune diseasesClinical trials
2017
Comparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†
Fang W, Yao X, Antonicelli A, Gu Z, Detterbeck F, Vallières E, Aye RW, Farivar AS, Huang J, Shang Y, Louie BE. Comparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 26-32. PMID: 28329118, PMCID: PMC6279116, DOI: 10.1093/ejcts/ezx042.Peer-Reviewed Original ResearchConceptsExtent of resectionThymic tumorsStage IAsian patientsSurgical approachOnly independent predictive factorMasaoka-Koga stage IMore stage IOutcomes of patientsPathological stage IIndependent predictive factorsIndependent risk factorOverall survival rateCumulative recurrence rateSmaller tumor sizeRetrospective database analysisNorth American patientsPartial thymectomyAdjuvant therapyParaneoplastic syndromeThymic carcinomaOverall survivalPerformance statusComplete resectionMyasthenia gravis
2015
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChi-Square DistributionChildDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factorsEditorial Commentary: Be Careful about Drawing Big Conclusions from Big Data
Detterbeck FC. Editorial Commentary: Be Careful about Drawing Big Conclusions from Big Data. Seminars In Thoracic And Cardiovascular Surgery 2015, 27: 4-5. PMID: 26074101, DOI: 10.1053/j.semtcvs.2015.02.008.Peer-Reviewed Original Research
2014
Thymic carcinoma outcomes and prognosis: Results of an international analysis
Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A. Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 95-101.e2. PMID: 25524678, DOI: 10.1016/j.jtcvs.2014.09.124.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'Proportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSex FactorsThymectomyThymomaThyroid NeoplasmsTime FactorsTreatment OutcomeConceptsRecurrence-free survivalEarly Masaoka stageR0 resectionOverall survivalRadiation therapyMasaoka stageThymic carcinomaMale genderLonger recurrence-free survivalMedian overall survivalStage IV diseaseAdjuvant radiation therapyMasaoka stage IPreoperative radiation therapyPrimary outcome measureSquamous cell carcinomaPredominant histologic subtypeAdjuvant chemotherapyImproved OSInduction chemotherapyProlonged OSCumulative incidenceHistologic subtypeMultivariable analysisTreatment patternsOutcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F, Committee E. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 103-109.e2. PMID: 25308116, DOI: 10.1016/j.jtcvs.2014.08.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemotherapy, AdjuvantDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNeuroendocrine TumorsProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsThymectomyThymus NeoplasmsTime FactorsTreatment OutcomeYoung AdultConceptsInternational Thymic Malignancy Interest GroupMasaoka-Koga stageOverall survivalCompleteness of resectionPrimary neuroendocrine tumorThoracic Surgeons databasePrognostic factorsHistologic subtypeSurgeons databaseNeuroendocrine tumorsHigher biologic aggressivenessMasaoka-Koga stage ICommon histologic subtypeMedian overall survivalEuropean SocietyRetrospective multicenter studyKaplan-Meier methodStrong prognostic factorLog-rank testInduction therapyAdjuvant treatmentCumulative incidenceResection statusComplete resectionMulticenter study
2011
Standard Terms, Definitions, and Policies for Minimally Invasive Resection of Thymoma
Toker A, Sonett J, Zielinski M, Rea F, Tomulescu V, Detterbeck FC. Standard Terms, Definitions, and Policies for Minimally Invasive Resection of Thymoma. Journal Of Thoracic Oncology 2011, 6: s1739-s1742. PMID: 21847056, DOI: 10.1097/jto.0b013e31821ea553.Peer-Reviewed Original Research